CN117338813A - Diarrhea dehydration rehydration liquid and preparation method thereof - Google Patents
Diarrhea dehydration rehydration liquid and preparation method thereof Download PDFInfo
- Publication number
- CN117338813A CN117338813A CN202311468949.XA CN202311468949A CN117338813A CN 117338813 A CN117338813 A CN 117338813A CN 202311468949 A CN202311468949 A CN 202311468949A CN 117338813 A CN117338813 A CN 117338813A
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- sodium
- glucose
- chloride
- dehydration rehydration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 106
- 230000018044 dehydration Effects 0.000 title claims abstract description 64
- 238000006297 dehydration reaction Methods 0.000 title claims abstract description 64
- 239000007788 liquid Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 83
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 81
- 239000008103 glucose Substances 0.000 claims abstract description 81
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 80
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 78
- 239000005715 Fructose Substances 0.000 claims abstract description 66
- 229930091371 Fructose Natural products 0.000 claims abstract description 66
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 66
- 239000001509 sodium citrate Substances 0.000 claims abstract description 43
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 43
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 42
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 42
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 42
- 239000011780 sodium chloride Substances 0.000 claims abstract description 41
- 239000001103 potassium chloride Substances 0.000 claims abstract description 40
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 40
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 239000000310 rehydration solution Substances 0.000 claims abstract description 16
- 235000002639 sodium chloride Nutrition 0.000 claims description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 235000011147 magnesium chloride Nutrition 0.000 claims description 10
- 235000011083 sodium citrates Nutrition 0.000 claims description 10
- 239000004376 Sucralose Substances 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 abstract description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 17
- 239000011777 magnesium Substances 0.000 abstract description 16
- 229910052749 magnesium Inorganic materials 0.000 abstract description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 10
- 239000011734 sodium Substances 0.000 abstract description 10
- 229910052708 sodium Inorganic materials 0.000 abstract description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 239000011591 potassium Substances 0.000 abstract description 9
- 229910052700 potassium Inorganic materials 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 7
- 235000000346 sugar Nutrition 0.000 abstract description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000460 chlorine Substances 0.000 abstract description 6
- 229910052801 chlorine Inorganic materials 0.000 abstract description 6
- 239000011574 phosphorus Substances 0.000 abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 208000005156 Dehydration Diseases 0.000 description 50
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 40
- 230000000694 effects Effects 0.000 description 21
- 230000000968 intestinal effect Effects 0.000 description 21
- 229940054269 sodium pyruvate Drugs 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 16
- 239000011670 zinc gluconate Substances 0.000 description 16
- 235000011478 zinc gluconate Nutrition 0.000 description 16
- 229960000306 zinc gluconate Drugs 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 229910001415 sodium ion Inorganic materials 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 235000006693 Cassia laevigata Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 241000522641 Senna Species 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000002637 fluid replacement therapy Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940124513 senna glycoside Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102100022719 Solute carrier family 2, facilitated glucose transporter member 5 Human genes 0.000 description 1
- 101710104292 Solute carrier family 2, facilitated glucose transporter member 5 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 238000009138 potassium supplementation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940076742 senna leaves Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a diarrhea dehydration rehydration liquid and a preparation method thereof. The diarrhea dehydration rehydration liquid comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride and 0.05-0.2g/L of magnesium chloride. The diarrhea dehydration rehydration solution of the invention is specifically supplemented with key electrolytes such as sodium, potassium, chlorine, magnesium and phosphorus that are easily lost in significant amounts during diarrhea. In addition, glucose and fructose are added to the formula to ensure that the body does not have gaps in energy supply, which not only provides necessary energy for the body, but also helps to maintain the stability of blood sugar. Through the synergistic effect of these materials, the present invention ensures that the body is adequately supported during diarrhea, thereby promoting faster recovery of the body.
Description
Technical Field
The invention relates to a diarrhea dehydration rehydration liquid and a preparation method thereof.
Background
Diarrhea is a common medical problem, often occurring for a variety of reasons, such as food poisoning, viral infections, bacterial infections, parasites, dyspepsia, drug reactions and other digestive tract diseases. In many cases, diarrhea can cause the body to lose a great deal of water and electrolytes, thereby causing dehydration, which can be fatal in certain people such as children, the elderly, and patients with disease.
In order to treat or prevent dehydration caused by diarrhea, various dehydration rehydration products are introduced on the market. These rehydration solutions are mostly based on oral dehydrated salt (ORS) formulations recommended by the World Health Organization (WHO) and the united nations children's foundation (UNICEF). Traditional ORS formulations mainly include glucose and some basic electrolytes, such as sodium and chlorine.
While these traditional ORS formulations have been successful worldwide in saving countless lives, they still have limitations in some respects. First, traditional ORS formulations often do not take into account the loss of other critical electrolytes, such as potassium, magnesium, and phosphorus, caused by diarrhea. These electrolytes are critical to the normal function of the cell and the overall health of the body. For example, loss of potassium may lead to muscle spasms and arrhythmias, while a lack of magnesium may trigger muscle weakness and neurological dysfunction.
Second, while glucose is the primary energy source of the body, reliance on glucose alone may not be sufficient to meet all of the energy needs of the body during diarrhea. In particular, diarrhea may result in a reduced glucose uptake by the gut, meaning that most of the glucose may be expelled from the body and fail to power the body.
In addition, conventional ORS formulations are generally free of alkaline buffers such as sodium citrate and sodium dihydrogen phosphate, meaning that they may not be effective in neutralizing intestinal acidification due to diarrhea, thereby affecting the acid-base balance and cellular function of the body.
Although the existing dehydrated rehydration products are still effective in many cases, their formulation is generally simpler and does not meet the various needs of diarrhea patients. In particular, in certain severe diarrhea situations, such as diarrhea due to food poisoning or pathogen infection, existing fluid supplements may not provide adequate support, thereby delaying recovery from the body.
In summary, the diarrhea dehydration rehydration solutions of the prior art, while capable of functioning in certain situations, still suffer from some significant drawbacks. In particular, these rehydration solutions tend to ignore certain critical electrolytes and energy sources that the body may lose during diarrhea, which may lead to slow recovery of the body and even complications.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a diarrhea dehydration rehydration solution and a preparation method thereof.
Specifically, the technical scheme of the invention is as follows:
the invention provides a diarrhea dehydration rehydration liquid, which comprises the following raw materials: water, glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride.
Preferably, the glucose content is 8-16g/L, preferably 10-14g/L.
Preferably, the crystalline fructose is present in an amount of 4-12g/L, preferably 6-10g/L.
Preferably, the sodium chloride content is 1.5-3.5g/L, preferably 2-3g/L.
Preferably, the sodium citrate is present in an amount of 4-6.5g/L, preferably 4.5-6g/L.
Preferably, the sodium dihydrogen phosphate content is 0.05-0.65g/L, preferably 0.1-0.5g/L.
Preferably, the potassium chloride content is 1-2g/L, preferably 1.2-1.8g/L.
Preferably, the magnesium chloride content is 0.03-0.25g/L, preferably 0.05-0.2g/L.
As a preferred embodiment, a diarrhea dehydration rehydration solution comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride and 0.05-0.2g/L of magnesium chloride.
Sour agents (such as citric acid), flavoring essence, sweeteners (such as sucralose) and the like can be added to improve the mouthfeel and olfactory experience. As a preferred embodiment, a diarrhea dehydration rehydration solution comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride, 0.05-0.2g/L of magnesium chloride, 0.2-0.4g/L of citric acid, 0.05-0.15g/L of essence and 0.1-0.3g/L of sucralose.
The invention also provides a preparation method of the diarrhea dehydration rehydration liquid, which comprises the following steps: glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly.
The diarrhea dehydration rehydration solution of the invention is specifically supplemented with key electrolytes such as sodium, potassium, chlorine, magnesium and phosphorus that are easily lost in significant amounts during diarrhea. In addition, glucose and fructose are added to the formula to ensure that the body does not have gaps in energy supply, which not only provides necessary energy for the body, but also helps to maintain the stability of blood sugar. Through the synergistic effect of these materials, the present invention ensures that the body is adequately supported during diarrhea, thereby promoting faster recovery of the body.
Detailed Description
The diarrhea dehydration rehydration liquid comprises the following raw materials: water, glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride.
As a preferred embodiment, a diarrhea dehydration rehydration solution comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride and 0.05-0.2g/L of magnesium chloride.
Glucose is the main energy source of the human body, and can provide necessary energy for cells, so that the body can normally operate, and the glucose is helpful for maintaining blood glucose stable, and avoiding energy shortage caused by diarrhea. Glucose enters the blood directly after ingestion, becomes blood glucose, and is then taken up by the cells in metabolic pathways for energy production. Mitochondria in a cell can convert glucose to Adenosine Triphosphate (ATP), which is the "energy currency" of the cell, through glycolysis and oxidative phosphorylation reactions. Especially in diarrhea, the body has an increased demand for energy due to accelerated metabolism by lost water and electrolytes. Therefore, timely glucose supplementation becomes critical in maintaining proper functioning of the body. In addition, the proper amount of glucose supplementation also helps to stabilize blood glucose, avoiding the occurrence of hypoglycemia, which may be a critical factor in certain situations, such as severe diarrhea.
Crystalline fructose may be converted to glucose upon ingestion, providing energy to the body. Furthermore, fructose may enhance glucose absorption when present with glucose. Fructose uptake is via a specific fructose transporter, and this process is not directly related to glucose uptake. Thus, when glucose and fructose are present simultaneously, they can be absorbed simultaneously and efficiently by the intestinal tract, thereby accelerating the energy supplementation. After entering the liver, fructose can be converted to glucose-6-phosphate via a series of enzymatic reactions, which is a key intermediate for gluconeogenesis and glycolysis, meaning that fructose can ultimately be converted to glucose and further supplied to the body as an energy source. In addition, studies have shown that fructose helps to promote the absorption of sodium, which in turn drives the absorption of glucose, meaning that fructose can enhance the glucose absorption effect, accelerating glucose uptake.
Glucose and fructose are absorbed in the small intestine by different mechanisms. Glucose absorption is primarily dependent on sodium-dependent active transport processes, whereas fructose is primarily absorbed by passive diffusion. (1) promote absorption of sugar by the small intestine: glucose can promote the absorption of fructose by the small intestine after ingestion of a food or beverage containing glucose and fructose. This is because glucose uptake results in a decrease in the sodium concentration inside the intestinal cells, allowing sodium to flow from the inside of the intestinal tract to the inside of the cells, increasing the concentration gradient of fructose, thus promoting its passive diffusion. (2) increase overall energy intake: since glucose and fructose are absorbed by different mechanisms, the rate of overall glucose absorption can be increased when they are present at the same time. This means that more energy can be taken from the food in a short time. (3) modulating the glycemic response: the metabolism of fructose in the body mainly proceeds in the liver, and does not raise blood glucose as rapidly as glucose. Thus, combining glucose and fructose intake may result in a relatively smooth glycemic response, which may be beneficial for maintaining a stable energy level and reducing severe fluctuations in insulin. (4) gluconeogenesis of liver: when fructose is ingested too much, fructose in the liver may be converted to glucose and then stored as glycogen or converted to fat. This means that there may be a metabolic balance between fructose and glucose at high doses. Overall, glucose and fructose, although similar in structure, have different biological roles and metabolic pathways. When taken together, these two sugars can form a synergistic effect in terms of absorption and metabolism, which can enhance energy intake, regulate glycemic response, and support gluconeogenesis of the liver when needed.
Sodium chloride acts primarily to replenish sodium and chloride ions lost due to diarrhea, thereby maintaining electrolyte balance in the body and maintaining normal cellular function. Sodium ions are the most predominant cations in extracellular fluids and are critical to maintaining fluid balance between and within cells. This balance determines the capacity and morphology of the cells. In addition, sodium ions also play an important role in neuromuscular excitability, affecting nerve impulse propagation and muscle contraction. The osmotic pressure of blood is also closely related to the concentration of sodium ions. Chloride ions are the most predominant anions in plasma and assist sodium ions in maintaining electrolyte balance while also helping to maintain acid-base balance and electronegativity in the body, particularly in erythrocytes. The chloride ions interact with other electrolytes to assist in the balance of moisture and other ions in the body.
Sodium citrate acts primarily as an alkaline buffer to maintain acid-base equilibrium in the body. At the same time, it also promotes the cleavage of sucrose in the stomach and small intestine, providing immediate energy. Citric acid is broken down in the body into alkaline products, helping to neutralize stomach acid, providing an alkaline environment, which in some cases can help maintain an acid-base balance. In addition, citric acid can promote the activity of certain enzymes, such as aiding in the breakdown of sucrose in the small intestine, thereby increasing the absorption of fructose and glucose.
Sodium dihydrogen phosphate supplements the phosphorus and sodium ions in the body, which is critical for acid-base balance and cellular function. Phosphate plays a buffering role in the body, helping to maintain acid-base balance, which is necessary for normal metabolism and function of cells. Phosphorus is also involved in cellular energy metabolism, particularly in the formation and breakdown of ATP (adenosine triphosphate). ATP is the primary energy source of cells and is critical for all vital activities. Phosphates are also involved in the synthesis and breakdown of many biomolecules, such as nucleic acids and lipids, and also play a key role in signal transduction. Sodium ions, as previously described, help maintain fluid and electrolyte balance and support normal nerve and muscle function.
Potassium chloride is a source of potassium and chlorine. Among them, the effect of potassium ion is particularly critical, since it has a critical effect on maintaining the normal function of cells. Sodium-potassium pumps on cell membranes maintain the membrane potential difference by regulating the intracellular and extracellular potassium and sodium ion concentrations. Maintaining this potential difference is the basis for normal electrophysiological activity of cells, particularly nerve and muscle cells. Diarrhea can lead to a substantial loss of potassium, thereby disrupting this potential balance, potentially leading to nerve and muscle dysfunction, such as weakness, muscle cramps or arrhythmias. Thus, potassium supplementation may not only help recover this potential difference, but may also prevent complications due to potassium deficiency.
Magnesium chloride is a source of chlorine and magnesium. Magnesium functions more complex and diverse than chlorine and is essential for many physiological processes of the body. Magnesium is a key component of ATP molecules for cell production energy. Without sufficient magnesium, cells cannot efficiently produce and use energy. Magnesium is necessary to maintain normal electrophysiological activity of the nerve cells. The lack of magnesium may cause nerve hyperexcitation, causing various symptoms of the nervous system, such as tremors, muscle spasms, and the like. Magnesium is critical to maintaining normal electrophysiological activity and heart rhythm. The lack of magnesium may increase the risk of arrhythmia. Diarrhea can lead to a substantial loss of magnesium, affecting all of the physiological processes described above. Therefore, the supplementation of magnesium can help to restore normal magnesium levels and maintain physical health.
The interaction between the materials not only ensures the balance of water and electrolyte during dehydration of diarrhea, but also provides the necessary energy to help the body return to healthy state as soon as possible. For example, the alkalinity of sodium citrate and sodium dihydrogen phosphate helps to neutralize intestinal acidification due to diarrhea, while glucose and fructose provide rapid energy supplementation to the body. In addition, supplementation of electrolytes such as sodium, potassium, and magnesium helps to maintain normal cell function, and prevents complications due to electrolyte imbalance. In diarrhea, the body rapidly loses a lot of water and electrolytes due to the rapid fluid removal from the intestine. This unbalanced condition is very dangerous. The rehydration formulation of the invention is intensively studied, and the synergistic effect between the ingredients can ensure that the body is sufficiently supported during diarrhea, thereby accelerating recovery.
Sour agents (such as citric acid), flavoring essence, sweeteners (such as sucralose) and the like can be added to improve the mouthfeel and olfactory experience. As a preferred embodiment, a diarrhea dehydration rehydration solution comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride, 0.05-0.2g/L of magnesium chloride, 0.2-0.4g/L of citric acid, 0.05-0.15g/L of essence and 0.1-0.3g/L of sucralose.
The rehydration regimen of the present invention is specifically supplemented for critical electrolytes such as sodium, potassium, chloride, magnesium and phosphorus that may be lost in significant amounts to the body during diarrhea. In order to ensure that the body is not influenced in energy, the formula is also blended with glucose and fructose, so that the energy requirement of the body is met, and the blood sugar level is stabilized. By virtue of the co-boosting of these components, the present invention provides a strong support for the body during diarrhea, helping the body to return to health more quickly.
Further, the inventors found that the performance was further improved after adding sodium pyruvate and/or zinc gluconate to the formulation. The content of the sodium pyruvate and/or zinc gluconate is 1-2g/L.
Preferably, the diarrhea dehydration rehydration liquid comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride, 0.05-0.2g/L of magnesium chloride, and 1-2g/L of sodium pyruvate and/or zinc gluconate.
Preferably, the diarrhea dehydration rehydration liquid comprises the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride, 0.05-0.2g/L of magnesium chloride, 0.5-1g/L of sodium pyruvate and 0.5-1g/L of zinc gluconate.
Effect of sodium pyruvate in the diarrhea dehydration rehydration of the present invention: (1) antacid action: diarrhea patients often accompany changes in intestinal pH, which may be due to unbalanced intestinal flora, incomplete food digestion, or other inflammatory causes. Sodium pyruvate has acid-resistant effect, can help to regulate pH value of intestinal tract, and provides more stable environment for electrolyte and sugar absorption. (2) anti-inflammatory action: inflammation may be one of the causes of diarrhea, especially in infectious diarrhea or inflammatory bowel disease. Sodium pyruvate has anti-inflammatory effects and may help to reduce intestinal inflammation, thereby improving symptoms and accelerating recovery. (3) antioxidation: the intestines of diarrhea patients may be damaged by oxidative stress due to free radicals and other oxides produced in the body. Sodium pyruvate has an antioxidant effect and may help to protect intestinal cells from such damage. (4) optimization of intestinal environment: sodium pyruvate may improve the intestinal environment during diarrhea and contribute to better absorption of other components, especially glucose and crystalline fructose. In addition, providing a better intestinal environment also helps to restore normal intestinal function.
Effect of zinc gluconate in the diarrhea dehydration rehydration of the present invention: (1) Zinc ion supplementation is particularly beneficial for the treatment of diarrhea, zinc can help shorten the duration and severity of diarrhea. (2) intestinal repair: zinc has growth promoting and repairing effects on intestinal epithelial cells, and can help repair intestinal damage, thereby helping to relieve diarrhea. (3) immunomodulation: zinc has an important role in the immune system and can enhance the immune response and help combat diarrhea-causing pathogens. (4) optimization of intestinal environment: zinc may have a modulating effect on the intestinal micro-organisms and help to restore and maintain the balance of intestinal flora. (5) binding to glucose: zinc gluconate is a zinc salt that is relatively easily absorbed. Glucose aids in zinc absorption, which ensures that the patient is effectively zinc supplemented.
Sodium pyruvate can improve intestinal environment caused by diarrhea, so that the sodium pyruvate is more beneficial to nutrient absorption. And zinc gluconate can accelerate the repair and growth of intestinal cells. The combination of the two components can help to quickly restore the intestinal function and absorb other components in the fluid replacement more efficiently. And the anti-inflammatory effect of sodium pyruvate and the immunopotentiation effect of zinc gluconate can cooperate to help the body to clear pathogens causing diarrhea more quickly and alleviate diarrhea symptoms.
In the examples and comparative examples of the present invention, the following are described for some raw materials:
glucose, the product standard code GB/T20880, is prepared from glucose (water) which is a high-grade product provided by Western Wang Yaoye Co.
Crystalline fructose, available from shan east and west king sugar industry, inc.
Example 1:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 5.16g/L sodium citrate, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride and 0.11g/L magnesium chloride.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Example 2:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 5.16g/L sodium citrate, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride, 0.11g/L magnesium chloride, 0.33g/L citric acid, 0.1g/L food essence and 0.2g/L sucralose.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride, magnesium chloride, citric acid, essence for food and sucralose are added into water, and the mixture is stirred and mixed uniformly, so that the diarrhea dehydration rehydration liquid of the invention can be prepared.
The osmotic pressure of the present invention is 270mOsmol/kg, and the present invention uses glucose and crystalline fructose as carbohydrate sources.
Example 3:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 5.16g/L sodium citrate, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride, 0.11g/L magnesium chloride and 1.5g/L sodium pyruvate.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride, magnesium chloride and sodium pyruvate are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Example 4:
the diarrhea dehydration rehydration liquid comprises the following raw materials: glucose 12g/L, crystalline fructose 8g/L, sodium chloride 2.34g/L, sodium citrate 5.16g/L, sodium dihydrogen phosphate 0.25g/L, potassium chloride 1.49g/L, magnesium chloride 0.11g/L, zinc gluconate 1.5g/L.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride, magnesium chloride and zinc gluconate are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Example 5:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 5.16g/L sodium citrate, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride, 0.11g/L magnesium chloride, 0.75g/L sodium pyruvate, and 0.75g/L zinc gluconate.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride, magnesium chloride, sodium pyruvate and zinc gluconate are added into water and stirred and mixed uniformly, so that the diarrhea dehydration rehydration liquid of the invention can be prepared.
Comparative example 1:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 5.16g/L sodium citrate, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride and 0.11g/L magnesium chloride.
Glucose, crystalline fructose, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 2:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 0.25g/L sodium dihydrogen phosphate, 1.49g/L potassium chloride and 0.11g/L magnesium chloride.
Glucose, crystalline fructose, sodium chloride, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 3:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 12g/L glucose, 8g/L crystalline fructose, 2.34g/L sodium chloride, 5.16g/L sodium citrate, 1.49g/L potassium chloride and 0.11g/L magnesium chloride.
Glucose, crystalline fructose, sodium chloride, sodium citrate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, so that the diarrhea dehydration rehydration liquid of the invention can be prepared.
Comparative example 4:
the diarrhea dehydration rehydration liquid comprises the following raw materials: glucose 12g/L, crystalline fructose 8g/L, sodium chloride 2.34g/L, sodium citrate 5.16g/L, sodium dihydrogen phosphate 0.25g/L and magnesium chloride 0.11g/L.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 5:
the diarrhea dehydration rehydration liquid comprises the following raw materials: glucose 12g/L, crystalline fructose 8g/L, sodium chloride 2.34g/L, sodium citrate 5.16g/L, sodium dihydrogen phosphate 0.25g/L, potassium chloride 1.49g/L.
Glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate and potassium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 6:
the diarrhea dehydration rehydration liquid comprises the following raw materials: crystalline fructose 20g/L, sodium chloride 2.34g/L, sodium citrate 5.16g/L, sodium dihydrogen phosphate 0.25g/L, potassium chloride 1.49g/L, magnesium chloride 0.11g/L.
Crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 7:
the diarrhea dehydration rehydration liquid comprises the following raw materials: glucose 20g/L, sodium chloride 2.34g/L, sodium citrate 5.16g/L, sodium dihydrogen phosphate 0.25g/L, potassium chloride 1.49g/L, magnesium chloride 0.11g/L.
Glucose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly, thus obtaining the diarrhea dehydration rehydration liquid.
Comparative example 8:
the diarrhea dehydration rehydration liquid comprises the following raw materials: 2.6g of sodium chloride, 2.9g of sodium citrate, 1.5g of potassium chloride and 13.5g of glucose are added to 1000ml of water.
Test example 1:
rabbits for health test have a weight of 2.0-2.4kg, and 20 rabbits for each group, wherein 10 rabbits are used for male and female animals. After 8h of fasted, 20mL/kg (rabbit weight) of senna She Shangji was infused, and all rabbits began to develop diarrhea after 1-3 hours. All rabbits were dosed 4 hours after the gastric laxative, in the following manner: the diarrhea was dehydrated and supplemented with 10mL/kg stomach, 2 times daily, 8 hours apart. Starting from the beginning of the administration, the effect of diarrhea treatment (complete cure/definite improvement/invalidation) was observed for the rabbits after 48 hours and the total number of defecations per group of 20 rabbits within 48 hours from the beginning of the administration was counted, and the results are shown in the following table.
Senna She Shangji: 20g of senna leaves are added into 1000ml of water and finally decocted into 200ml of senna She Shangji.
The diarrhea treatment effect: (1) "complete cure" means complete elimination of diarrhea dehydration symptoms; (2) "certain improvement" means alleviation of diarrhea dehydration symptoms; (3) "ineffective" indicates that the mice die or diarrhea is aggravated.
Blank group: gastric lavage 10mL/kg physiological saline, 2 times daily at 8 hours intervals.
Examples 1-5 are five formulas of diarrhea dehydration rehydration, and comparative examples 1-8 are substitutions or deletions of one or more components of the original formulas to observe the effects. The following are analyses of these examples and comparative examples:
1. treatment effect analysis:
the "complete cure" condition of examples 1-5 is significantly better than the comparative examples 1-8 and the blank. The effect of the blank group was the worst, only 1 rabbit was completely cured, and 1 rabbit died.
2. Total bowel movement count analysis:
the rabbits of example 5 had a minimum total number of bowel movements (124) within 48 hours of administration, indicating a good control of diarrhea. In example 5, sodium pyruvate and zinc gluconate together play a key role in the dehydration and fluid replacement of diarrhea, and sodium pyruvate stabilizes intestinal tract pH and facilitates nutrient absorption; zinc gluconate promotes intestinal cell growth and maintains intestinal flora balance. The two cooperate to provide an optimal intestinal repair environment. Sodium pyruvate has anti-inflammatory and antioxidant effects, and can reduce inflammation. Zinc gluconate enhances the immune response and helps to clear pathogens. The combination of the two enhances the absorption of the components in the fluid replacement and provides nutrition support. In conclusion, the combination of the two can accelerate intestinal repair, enhance immunity and provide a quick recovery path for diarrhea patients.
The total number of bowel movements in the blank group was greatest, reaching 424, indicating little therapeutic effect of normal saline on diarrhea.
3. Analysis of the formulation:
the base formulation of example 1 has good results for the treatment of diarrhea. Similar effects were obtained when citric acid, food flavor and sucralose were added in example 2; the addition of sodium pyruvate in example 3 or zinc gluconate in example 4 gives better results.
From comparative examples 1 to 7, the absence of any one of the main components (e.g., sodium chloride, sodium citrate, sodium dihydrogen phosphate, etc.) resulted in a decrease in the therapeutic effect.
The differences between comparative example 8 and the other comparative examples and examples are mainly the concentration and type of raw materials. The effect of comparative example 8 was the worst, which may indicate that this formulation was less effective in treating diarrhea than other formulations.
The applicable population of the invention is the population which is more than 10 years old and needs water and electrolyte for light-to-moderate dehydration caused by diarrhea and the like.
The eating method and the eating amount of the invention are as follows: it is administered directly after opening. The eating method and the eating amount should be comprehensively determined according to the age, weight, medical condition and the like of the applicable people under the guidance of doctors or clinical nutritionists.
Alert description and notice of the present invention:
1. please use under the direction of a doctor or clinical nutrition technician.
2. The product is prohibited for parenteral nutrition support and intravenous injection.
3. Is not suitable for non-target people.
4. The product can not be used as a single nutrient source.
5. Misuse may cause health hazards.
6. In clinical use, care should be taken to monitor serum ion concentrations of the elements involved in the product.
7. The product is not suitable for the following patients: ileus, severe heart and kidney dysfunction, etc.
Claims (10)
1. The diarrhea dehydration rehydration liquid is characterized by comprising the following raw materials: water, glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride.
2. The diarrhea dehydration rehydration solution of claim 1 wherein the glucose content is 8-16g/L.
3. The diarrhea dehydration rehydration solution of claim 1 wherein the crystalline fructose is present in an amount of 4-12g/L.
4. The diarrhea dehydration rehydration solution of claim 1 wherein the sodium chloride is present in an amount of 1.5-3.5g/L.
5. The diarrhea dehydration rehydration solution of claim 1 wherein the sodium citrate is present in an amount of 4-6.5g/L.
6. The diarrhea dehydration rehydration solution of claim 1 wherein the sodium dihydrogen phosphate is present in an amount of 0.05 to 0.65g/L.
7. The diarrhea dehydration rehydration of claim 1, wherein the potassium chloride is present in an amount of 1-2g/L and the magnesium chloride is present in an amount of 0.03-0.25g/L.
8. The diarrhea dehydration rehydration solution as recited in any one of claims 1-7, comprising the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride and 0.05-0.2g/L of magnesium chloride.
9. The diarrhea dehydration rehydration of claim 8, comprising the following raw materials: 10-14g/L of glucose, 6-10g/L of crystalline fructose, 2-3g/L of sodium chloride, 4.5-6g/L of sodium citrate, 0.1-0.5g/L of sodium dihydrogen phosphate, 1.2-1.8g/L of potassium chloride, 0.05-0.2g/L of magnesium chloride, 0.2-0.4g/L of citric acid, 0.05-0.15g/L of essence and 0.1-0.3g/L of sucralose.
10. The method for preparing the diarrhea dehydration rehydration liquid according to any one of claims 1 to 9, comprising the following steps: glucose, crystalline fructose, sodium chloride, sodium citrate, sodium dihydrogen phosphate, potassium chloride and magnesium chloride are added into water and stirred and mixed uniformly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311468949.XA CN117338813A (en) | 2023-11-07 | 2023-11-07 | Diarrhea dehydration rehydration liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311468949.XA CN117338813A (en) | 2023-11-07 | 2023-11-07 | Diarrhea dehydration rehydration liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117338813A true CN117338813A (en) | 2024-01-05 |
Family
ID=89364843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311468949.XA Pending CN117338813A (en) | 2023-11-07 | 2023-11-07 | Diarrhea dehydration rehydration liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117338813A (en) |
-
2023
- 2023-11-07 CN CN202311468949.XA patent/CN117338813A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5716926A (en) | Composition of pyruvate and protein and method for increasing protein concentration in a mammal | |
| US9757345B2 (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| Hyman et al. | Parenteral and oral alimentation in the treatment of the nonspecific protracted diarrheal syndrome of infancy | |
| US5431925A (en) | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | |
| Sheldon et al. | Phosphate depletion and repletion: relation to parenteral nutrition and oxygen transport. | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| EP1797891A1 (en) | Total enteral nutritious composition | |
| KR102057555B1 (en) | Carboxylic Acid Mixtures to Treat Patients with Renal Failure | |
| EA025137B1 (en) | Dialysis solution comprising one or more creatine compounds and method for preparing the same | |
| WO2008014674A1 (en) | A nutritional and health-care edible potassium salt with wide purpose | |
| Meeuwisse et al. | GLUCOSE‐GALACTOSE MALABSORPTION: A Clinical Study of 6 Cases | |
| SE464059C (en) | Use of inositol triphosphate for drug preparation | |
| US20070048354A1 (en) | Synthetic nutritional formulations | |
| US20180049983A1 (en) | Liposomal rehydration salt formulation and associated methods of use | |
| KR20200016608A (en) | The health food composition for regulating weight | |
| CN117338813A (en) | Diarrhea dehydration rehydration liquid and preparation method thereof | |
| Minot et al. | Guanidine intoxication: a complicating factor in certain clinical conditions in children | |
| CN113519850A (en) | Tumor total nutrient emulsion, preparation method and application thereof | |
| CN112715961A (en) | Food composition for promoting muscle growth of elderly diabetic patients | |
| Brophy et al. | Clinical drug therapy for Canadian practice | |
| WO2005041949A1 (en) | Composition for the treatment of dysfunctional energy metabolism syndrome | |
| RU2400251C1 (en) | Method of treating chronic kidney disease in predialytic and dialytic periods and medication for its realisation | |
| US7998500B2 (en) | Nutritional supplement for women | |
| CN110538315A (en) | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |